Key result
Transapical off-pump mitral valve repair with the NeoChord DS1000 device achieved 100% procedural success and resulted in nonsignificant mitral regurgitation in 81% of patients at 6 months.
Why the study?
To evaluate early results of MV repair using the NeoChord DS1000 device in the first consecutive series of patients operated on in Poland.
Does transapical off-pump mitral valve repair with the NeoChord DS1000 device reduce mitral regurgitation in patients with severe MR due to posterior leaflet prolapse?
Observational (n=21)
No
Does transapical off-pump mitral valve repair with the NeoChord DS1000 device reduce mitral regurgitation in patients with severe MR due to posterior leaflet prolapse?
Transapical off-pump mitral valve repair with the NeoChord DS1000 device is feasible and effectively reduces mitral regurgitation and promotes reverse remodeling at 6 months in selected patients.
No takes yet. Share an insight, caveat, or question.
Supports short-term MR reduction with NeoChord in selected prolapse patients; hypothesis-generating, requires randomized trials before practice change.
Kurnicka et al. (2019) conducted an observational in Severe mitral regurgitation due to posterior leaflet prolapse (n=21). NeoChord DS1000 device was evaluated on Nonsignificant mitral regurgitation (trace or mild) at 6 months. Transapical off-pump mitral valve repair with the NeoChord DS1000 device achieved 100% procedural success and resulted in nonsignificant mitral regurgitation in 81% of patients at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: